申请人:Zhang Qiang
公开号:US20130035350A1
公开(公告)日:2013-02-07
This disclosure concerns novel quinazoline compounds of Formula (I) as defined in the specification and compositions comprising such novel compounds. These compounds are useful anticancer agents, especially in inhibiting the function of the EGF receptor tyrosine kinases, HER1 tyrosine kinase, and HER2 tyrosine kinase. Thus, the disclosure also concerns a method of treating hyperproliferative diseases or conditions, such as various cancers and benign prostate hyperplasia (BPH), by use of these novel compounds or a composition comprising such novel compounds.
本公开涉及式(I)中定义的新型喹唑啉化合物及包含这些新型化合物的组合物。这些化合物是有用的抗癌剂,特别是在抑制EGF受体酪氨酸激酶、HER1酪氨酸激酶和HER2酪氨酸激酶的功能方面。因此,本公开还涉及使用这些新型化合物或包含这些新型化合物的组合物治疗过度增殖性疾病或病状,例如各种癌症和良性前列腺增生症(BPH)的方法。